Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCQ | Q04759 | 17/20 | 0.59 |
| ▸ | PRKCD | Q05655 | 17/20 | 0.59 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.43 |
| ▸ | PRKCH | P24723 | 2/20 | 0.43 |
| ▸ | PRKCE | Q02156 | 2/20 | 0.43 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.42 |
| ▸ | PRKCB | P05771 | 1/20 | 0.42 |
| ▸ | LCK | P06239 | 1/20 | 0.42 |
| ▸ | LYN | P07948 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2979273 | 0.87 | PRKCQ (0.70) | PRKCQPRKCDPRKCHPRKCEPRKCB | |
| SCHEMBL2980364 | 0.75 | PRKCQ (0.73) | PRKCQPRKCDPRKCHPRKCEPRKCB | |
| SCHEMBL2984352 | 0.74 | PRKCQ (0.53) | PRKCQPRKCDTRPA1PRKCHPRKCE | |
| SCHEMBL2985945 | 0.74 | PRKCQ (0.59) | PRKCQPRKCDPRKCHPRKCE | |
| SCHEMBL2985570 | 0.74 | PRKCQ (0.79) | PRKCQPRKCDPRKCHPRKCEPRKCB | |
| SCHEMBL2983452 | 0.74 | PRKCQ (1.00) | PRKCQPRKCDPRKCHPRKCEPRKCB | |
| SCHEMBL4247140 | 0.74 | PRKCQ (0.57) | PRKCQPRKCDPRKCHPRKCE | |
| SCHEMBL2984601 | 0.73 | PRKCQ (0.53) | PRKCQPRKCDPRKCHPRKCEPRKCB | |
| SCHEMBL5332616 | 0.73 | MAPKAPK2 (0.45) | MAPKAPK2 | |
| SCHEMBL2984975 | 0.73 | PRKCQ (0.78) | PRKCQPRKCDPRKCHPRKCE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2029543-B1 | SUBSTITUTED 3-CYANOPYRIDINES AS PROTEIN KINASE INHIBITORS | WYETH LLC (US) | 2015-11-18 | — | — | EP | claimed |
| EP-2029543-A2 | SUBSTITUTED 3-CYANOPYRIDINES AS PROTEIN KINASE INHIBITORS | Wyeth (US) | 2009-03-04 | — | — | EP | claimed |
| WO-2007146376-A2 | SUBSTITUTED 3-CYANOPYRIDINES AS PROTEIN KINASE INHIBITORS | WYETH (US) | 2007-12-21 | — | — | WO | claimed |
| US-20070287708-A1 | Substituted 3-cyanopyridines as protein kinase inhibitors | WYETH LLC | 2007-12-13 | — | — | US | claimed |
| EP-2029543-B1 | SUBSTITUTED 3-CYANOPYRIDINES AS PROTEIN KINASE INHIBITORS | WYETH LLC (US) | 2015-11-18 | — | — | EP | disclosed |
| US-7781591-B2 | Substituted 3-cyanopyridines as protein kinase inhibitors | WYETH LLC (US) | 2010-08-24 | — | — | US | disclosed |
| US-20070287708-A1 | Substituted 3-cyanopyridines as protein kinase inhibitors | WYETH LLC | 2007-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070287708-A1 | Substituted 3-cyanopyridines as protein kinase inhibitors | CNKSR1, MAP3K1, MAP3K7 | PRKCQ 165/4885PRKCD 323/4885TRPA1 2815/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.